Key statistics
On Friday, C4 Therapeutics Inc (CCCC:NSQ) closed at 1.89, 74.19% above the 52 week low of 1.09 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.85 |
|---|---|
| High | 1.97 |
| Low | 1.85 |
| Bid | 1.85 |
| Offer | 1.90 |
| Previous close | 1.83 |
| Average volume | 874.89k |
|---|---|
| Shares outstanding | 96.91m |
| Free float | 89.94m |
| P/E (TTM) | -- |
| Market cap | 183.17m USD |
| EPS (TTM) | -1.67 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
- C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
- C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
- C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
- C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
- C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
More ▼
